国际新辅助黑色素瘤联盟:黑色素瘤新辅助系统治疗推荐
国际新辅助黑色素瘤联盟由多学科专家组成,针对临床可检测的III期黑色素瘤患者新辅助治疗研究提出推荐,以统一未来试验设计与转化分析。联盟旨在协调新辅助试验的设计、终点和分析,优化数据组织以利于监管审评并加强转化研究。
要点
- 临床可检测III期黑色素瘤患者是新辅助治疗的理想候选人群。
- 新辅助治疗研究需统一设计、终点和分析以利于数据整合与监管审评。
- 联盟推荐旨在协调试验设计并加强黑色素瘤全程转化研究。
核心结论
- 国际新辅助黑色素瘤联盟提出推荐以统一黑色素瘤新辅助治疗试验设计与转化分析。
研究设计与样本
- 国际新辅助黑色素瘤联盟由肿瘤内科、外科肿瘤、病理、放射肿瘤、影像和转化研究专家组成并制定推荐。
主要发现
- 临床可检测III期黑色素瘤患者仅 upfront 手术预后差,是新辅助治疗的理想候选人群。
- 自2014年以来黑色素瘤新辅助治疗已有大量完成和正在进行的试验,但设计、终点和分析不一致。
临床怎么用
- 联盟推荐可用于协调未来黑色素瘤新辅助试验的设计、终点和转化分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.
引用
- Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019. PMID: 31267972. doi:10.1016/S1470-2045(19)30332-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。